FDA approves blood test for colon cancer detection | CBS News
Excerpt from CBS News: “The Food and Drug Administration approved a blood test intended to detect colorectal cancer on Monday, expanding options for screening for the potentially deadly disease. The blood test, called Shield, from company Guardant Health, Inc., is approved for screening adults age 45 and older who are at average risk for the disease. The approval follows promising results from a clinical study of the blood test from earlier this year.” Read More.
Pfizer lifts profit forecast as investors await turnaround | Reuters
Excerpt from Reuters: “Pfizer raised its annual profit forecast on Tuesday, helped by cancer treatments acquired through a $43 billion deal for Seagen and strong sales of its heart disease drug as the company deals with a sharp revenue drop from COVID products. The market for Pfizer’s COVID-19 vaccine and treatment has shrunk by billions of dollars a year. Pfizer CEO Albert Bourla responded with several acquisitions, including the Seagen deal and cost-cutting measures. The New York-based drugmaker also has sharpened its focus on cancer treatments.” Read more.
Amneal Pharmaceuticals Gets Additional FDA New Drug Application Approval | MarketWatch
Excerpt from MarketWatch: “Amneal Pharmaceuticals said the U.S. Food and Drug Administration approved its new drug application for its potassium phosphates in sodium chloride injection, available as a single-dose infusion bag. The pharmaceutical company on Monday said that the injection is a phosphorus replacement product indicated as a source of phosphorus to correct hypophosphatemia in adults and pediatric patients when oral or replacement is not possible, insufficient or contraindicated.” Read More.
Sorry, the comment form is closed at this time.